People on the Move
Kymab
Kymab, a biopharmaceutical company in Cambridge, UK, has looked outside the company to fill the roles of Chief Scientific Officer (CSO) and VP and Head of Business Development.
Steve Arkinstall, the new CSO, joins Kymab from Merck Serono, where he worked in senior positions for 16 years, including leading the Serono Research Institute in Boston. He has also worked in research at GlaxoWellcome.
Kymab described Nigel Clark, now VP and Head of Business Development, as “a recognised deal maker,” having completed more than 20 major transactions, with experience in the biopharmaceutical industry at both public and private companies. He was previously Chief Business Officer at Syntaxin and negotiated the sale of the company to Ipsen Pharma for €158 million ($215m).
Allan Bradley, Kymab’s founder, will vacate his role as Chief Scientific Officer but will continue as a member of the Executive Leadership team and will take on the position of Chief Technology Officer.
